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We and others have shown that potassium loss is a requisite apoptotic event in 
mammalian cortical and midbrain neuronal systems. Potassium loss after oxidative injury is 
mediated through an increase in the soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor-mediated channel insertion of the delayed rectifier voltage-gated potassium channel 
Kv2.1. This occurs through the dual phosphorylation mechanism of S800 and Y124, mediated by 
p38 and Src respectively. Inhibiting the potassium current surge is enough to block neuronal cell 
death in models of neuronal injury. Thus, targeting this cellular apoptotic pathway could provide 
novel therapeutic strategies in neuroprotection for diseases such as Alzheimer’s, Parkinson’s, 
and ischemic stroke. Recently the hepatitis C virus (HCV) non-structural 5A (NS5A) protein was 
found to confer anti-apoptotic properties through the same pathway in hepatocytes, contributing 
to viral persistence. Here we show that expression of NS5A (genotype 1b) in neurons limits 
Kv2.1 functional expression, modulates the pro-apoptotic potassium current surge, and is 
neuroprotective. Importantly, we define a mechanism for this regulation whereby NS5A1b 
inhibits Src phosphorylation at the Y124 residue of Kv2.1. These anti-apoptotic effects are not as 
profound in cells expressing NS5A of the 1a genotype, suggesting that these effects are 
genotype-selective. Preliminary results inhibiting Casein Kinase II, known to phosphorylate 
NS5A, lead us to speculate that post-translational modifications are required for K+ current 
modulation. Our results indicate that NS5A1b maintains neuronal viability after injury via Kv2.1 
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current modulation, and that this could translate to improved therapies in neuroprotection. It is 
therefore likely that this pathway is critical for NS5A-induced adaptation of host cell activity for 
maximizing and perpetuating hepatic viral infection. 
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1.0  INTRODUCTION 
1.1 POTASSIUM HOMEOSTASIS IN APOPTOSIS 
Neuronal apoptosis via oxidative damage occurs in a myriad of neurodegenerative 
diseases, including Alzheimer’s disease, Parkinson’s disease and ischemic injury leading to 
stroke. Many advances have been made including the development of therapies leading to 
clinical trials, although successful neuro-protective treatments for these conditions remain 
elusive. Seeking a solution to this problem, two groups discovered that maintaining decreased 
potassium levels inside cortical and midbrain neurons contributes to a unique anti-apoptotic 
environment. They also demonstrated that potassium loss is an essential signal in many cell 
death pathways 1,2. The loss of intracellular K+, the most abundant cation within the cell, is a 
good candidate for the ionic regulation of apoptosis as it can deliver effective cell death signals 
without turning on propagated suicide programs that could be extensively deleterious. Levels can 
drop as low as 35 mM from established concentrations of ~140 mM, providing a suitable 
environment for caspase and nuclease activation, as well as playing a critical role in the apoptotic 
volume decrease 3. Importantly, interfering with the processes responsible for the apoptotic K+ 
current surge can effectively block neuronal cell death following oxidative injury 2,4-7. Thus, 
targeting this cellular apoptotic pathway could provide novel therapeutic strategies in 
neuroprotection. 
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Voltage-gated K+ (Kv), outward delayed rectifier (IK) channels are specifically poised to 
efflux potassium in large quantities due to their voltage dependence, slow-inactivation in 
response to depolarization, and ability to conduct K+ well 3. Indeed, Yu et al (1997) found that in 
cortical neurons, the apoptotic, caspase 3 activator staurosporine was associated with K+ current 
enhancement in as early as 3 hours after treatment, and that keeping intracellular levels of 
potassium high blocked this cell death. Similar studies were confirmatory of this phenomenon in 
other apoptotic pathways 8. One such cell death pathway, which our laboratory has worked to 
characterize, is described in Figure 1. An oxidative insult such as reactive oxygen species (ROS), 
an oxidizing agent or peroxynitrite leads to the liberation of intracellular zinc from metal binding 
proteins such as metallothionein 9. Through either mitochondria 10 or 12-lipoxygenase (an 
enzyme with a byproduct of superoxide) 11. Zinc then leads to additional ROS production which 
then activates the apoptosis signal regulating kinase (ASK-1) 6,12. ASK-1 phosphorylates the 
mitogen activated protein kinase (MAPK) p38, which leads to the enhancement of K+ currents 7 
and downstream caspase activation 6,11-13. 
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Figure 1. Schematic diagram of proposed pathway of enhancement of Kv2.1-mediated K+ currents.   
Oxidants trigger the liberation of intracellular zinc from metal binding proteins, which activates 
the p38 MAPK pathway 6. P38 directly phosphorylates Kv2.1, promoting membrane SNARE-
dependent insertion of the channel 14, a subsequent surge of Kv2.1 activity, and leads to neuronal 
apoptosis 15. This is a necessary step in apoptosis, as caspases are inhibited by physiological 
levels of the cation. ROS, reactive oxygen species; RNS, reactive nitrogen species (adapted from 
Redman et al 2009a). 
 
 
 
Kv2.1, the channel responsible for most IK current in cortical neurons 16,17, is responsible 
for the distinctive surge in these cells, demonstrated in our laboratory in part by using Kv2.1 
dominant negative constructs 7. This process is triggered by the dual phosphorylation mechanism 
of Kv2.1 residues S800 and Y124, mediated by p38 and Src respectively (Figure 2) 15,18. This 
promotes membrane insertion of the channel via soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE)-dependent channel insertion, rather than in gating 
characteristics of channels already present in the plasma membrane 7,14,15. Inhibiting the 
potassium surge, through the blockade of channel membrane insertion, for example, is enough to 
block neuronal cell death in certain models of injury 6,7,19. 
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Figure 2. Schematic of Kv2.1 residues required for K+ current enhancement during neuronal 
apoptosis.  
The trans-membrane Kv2.1 protein is phosphorylated at n-terminal Y124 and c-terminal S800 
residues by Src and p38 MAPK respectively. Both N and C termini are cytoplasmic (adapted 
from Redman et al 2009b). 
 
1.2 HCV NS5A BLOCKS THE K+ CURRENT SURGE IN LIVER CELLS 
UNDERGOING APOPTOSIS 
It was recently shown that this K+ channel-dependent pathway is observed in hepatocytes 
undergoing apoptosis 20. Hepatocyte cell death happens constantly as these cells turn over under 
normal conditions, but infection with the hepatitis C virus (HCV) interferes with normal cell 
death processes. To mediate persistent infection, the virus must replicate its genome, as well as 
disrupt normal cell physiology to hinder cellular apoptosis, produced either by normal cell 
turnover or by the virus itself 21. Still, there is a scarcity of published data detailing the molecular 
mechanisms by which this occurs. Because ion channels have been implicated in viral apoptotic 
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programs 22, HCV may act to disrupt channel function during this process. Indeed, Mankouri et 
al. (2009) established that delayed rectifying K+ current activity was diminished in hepatoma 
cells expressing the non-structural 5A (NS5A) HCV protein. They also showed that these 
currents did not demonstrate a surge following oxidative treatment with the thiol oxidant 
2,2’ ‐dithiodipyridine (DTDP), a known activator of the previously defined pathway 4,6. 
Mankouri et al. (2009) found the primary channel involved in protection was Kv2.1, and 
proposed that it occurred through a p38 MAPK ‐dependent mechanism   lls carry 
out robust RNA replication of the virus in vitro when expressing a full replicon, which was used 
by Mankouri et al. (2009) in most experimental procedures. However, importantly, NS5A alone 
was sufficient to suppress K+ current enhancement in these cells. It is therefore likely that this 
pathway is critical for NS5A ‐induced adap         
perpetuating hepatic viral infection, perhaps by increasing viral persistence. Thus, we 
hypothesized that cortical neurons may respond to NS5A through a similar mechanism. 
  
We report here that NS5A1b modulates basal neuronal K+ currents, limits the current 
surge, and protects neurons from apoptosis after injury. Further, we have elucidated the 
mechanism of action, demonstrating that this protein interferes with Src-mediated 
phosphorylation of Y124 on Kv2.1. The modulation of apoptosis, however, is not as pronounced 
in NS5A of the 1a genotype, which led us to speculate that this is due to genotypic divergence, 
perhaps related to differential modifications as a result of interactions with host proteins.  
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2.0  METHODS 
2.1 MATERIALS 
The NS5A-expression vectors were kindly provided by Dr. Mark Harris (Institute of 
Molecular and Cellular Biology, University of Leeds, Leeds, UK; 20. The Kv2.1 mammalian 
expression vector was given by J. Trimmer (UC Davis), and the Kv2.1 (Y124) mutant from A. 
Elson (Weizmann Institute, Rehovot, Israel). All other Kv2.1 mutants were generated as 
described 15. Chemicals and other materials were obtained from Sigma-Aldrich (St Louis, MO, 
USA) unless otherwise noted. 
2.2 CELL CULTURE AND TRANSFECTION PROCEDURES 
Cortical neuronal cultures were prepared in accordance with The University of Pittsburgh 
Institutional Animal Care and Use Committee, and as previously described from embryonic day 
16 Sprague-Dawley rats 23. Cortices were dissociated with trypsin and cells were plated on 11-
mm poly-L-ornithine or poly-L-lysine-treated coverslips in a growth medium composed of 80% 
Dulbecco’s modified minimal essential medium, 10% Ham’s F12-nutrients, and 10% bovine calf 
serum (heat-inactivated and iron-supplemented) with 25 mM HEPES, 24 U/ml penicillin, 24 
µg/ml streptomycin. Cells were maintained in 5% CO2 at 37oC, and medium was partially 
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replaced three times a week. Non-neuronal cell proliferation was inhibited after 2 weeks in 
culture with 1–2 mM cytosine arabinoside, and the medium was reduced to 2% serum without 
F12-nutrients. At 3–5 weeks in vitro these cultures contain 10–20% neurons 24. 
Electrophysiology was performed on 3 to 4-week-old cultures (19-26 days in vitro), and toxicity 
assays were performed on 4-week-old cultures (25-29 days in vitro). Neurons were transfected as 
previously described 7 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacture’s instructions with a plasmid encoding NS5A1b-eGFP, NS5A1a, NS5A1a (PA2) or 
their parent vectors eGFP or PSG5, as noted, and with enhanced GFP to increase the ability to 
select transfected cells for electrophysiology. For toxicity assays, cells were transfected with a 
luciferase-expressing vector 7,25-27 along with the above plasmids, as noted in the text. Cells were 
transfected with 1.5 µg of plasmid DNA in a 24-well plate, and media was replaced 3-5 hours 
after transfection. Cells were used for electrophysiology or treated with microglia for toxicity 
studies 24 hours after transfection.  
 
Chinese hamster ovary (CHO) cells were maintained as described with minor alterations 
15. Maintenance media consisted of F12 nutrient medium with 10% FBS and cells were cultured 
at 5% CO2, 37oC. 24 hours before transfection (as above, with 1.4 µg DNA per 6-well plate 
containing 5 cover slips) cells were plated at 2.8 x 105 cells per well. After transfection, media 
was replaced with serum free, containing 10 mM HEPES for 2-4 hours. Cells were then 
maintained with serum-containing media, and recordings were performed 24 hours after 
transfection. For biochemical experiments, CHO cells were seeded at a density of 1.7 x 106 in 
100 mm dishes and transfected as described with 7.334 µg DNA per dish. CHO cells were 
 8 
transfected for electrophysiology or biochemistry with WT Kv2.1 or mutants S800E, S800A, 
Y124F; NS5A1b, 1a, PA2, or parent vectors; and Src or p38 as noted.  
 
Immortalized rat brain microglia (HAPI cells) were cultured, plated and activated as 
previously described 27-29. Microglia were maintained in Dulbecco’s modified MEM 
supplemented with 10% heat-inactivated fetal bovine serum. For electrophysiological studies, 
cells were plated in trans-well inserts at a density of 0.5 ×106 cells/well for 24 hours prior to 
placing the inserts on top of neuronal cultures and activating the microglia with 10 U/mL 
interferon-γ (IFN-γ) and 1 μg/mL lipopolysaccharide (LPS) for 60 min. This leads to oxidative 
stress conditions from activated iNOS and NADPH oxidase 28,30,31. For toxicity assays, cells 
were plated directly onto neuronal cultures at a density of 0.25 × 106 cells per well and activated 
with IFN-γ and LPS for 24 hours before viability assessment. 
2.3 DRUG TREATMENT 
For inhibition of Casein Kinase II 5-Oxo-5,6-dihydroindolo-[1,2-a]quinazolin-7-acetic 
acid (IQA, Casein Kinase II Inhibitor IV, Calbiochem, Gibbstown, NJ), was used; a 
indoloquinazoline derivative that suppresses CK2 activity in vitro with an IC50 of 0.39 µM. This 
inhibitor, specific for CK2 with minimal activity with 44 other kinases, takes advantage of a 
relatively smaller ATP active site within CK2, as IQA competes with ATP for binding there 32. 
In indicated experiments, IQA (10 µM) was added with conditioned media 4 hours after 
transfection, and was present in the external recording solution for electrophysiological 
measurements. 
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2.4 ELECTROPHYSIOLOGICAL MEASUREMENTS 
Recordings were performed on transfected neurons or CHO cells, as evidenced by eGFP-
positive cells at room temperature using the whole cell patch clamp technique with 2–3 MΩ 
patch electrodes 6. Electrodes were pulled with a model P-97 mechanical pipette puller (Sutter 
Instruments, Novato, CA) from 1.5 mm borosilicate glass (Warner instruments, Hamden, CT). 
Statistical analysis was performed using InStat software along with Origin for graphic design.  
 
For voltage clamp recordings extracellular recording solution contained (in mM): 115 
NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 d-glucose, pH 7.2; 0.25 μM tetrodotoxin was added to 
block Na+ channels. The electrode (internal) solution consisted of (in mM): 100 K-gluconate, 11 
EGTA, 10 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, 2.2 Mg2ATP, 0.33 GTP; pH 7.2. Osmolarity was 
adjusted to 280 mOsm with sucrose. Currents were measured with an Axopatch 200B amplifier 
(Axon Instruments) and pClamp software (Molecular Devices, Sunnyvale, CA), filtered at 2 
kHz, and digitized at 10 kHz. Following a depolarizing pre-pulse to inactivate A-type, transient 
outward K+ currents, potassium currents were evoked with 80-ms voltage steps from −70 mV in 
10-mV increments to 50mV. For analysis and determination of current densities, steady state 
current amplitudes were measured at + 10 mV and normalized to cell capacitance. Series 
resistance was compensated (~80%). Neurons previously exposed to activated microglia (AMG) 
were washed and media was replaced with media containing butoxy-carbonyl-aspartate-
fluoromethyl ketone (BAF; 10 µM) to prevent downstream caspase-induced cell death, and the 
inability to perform electrophysiological recordings. Cells were recorded from 2-5 hours after 
AMG addition.  
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For current clamp recordings the extracellular solution contained (in mM): 146 NaCl, 7.8 
glucose, 20 HEPES, 4.7 KCl, 0.6 MgSO4, 1.6 NaHCO3, 0.13 NaH2PO4, 2.5 CaCl2; pH 7.3, 
bubbled with 100% O2. The electrode solution contained (in mM): 94 K+-gluconate, 30 KCl, 10 
Phosphocreatine di tris salt, 10 HEPES, 0.2 EGTA, 4 Mg2ATP, 0.3 Na2GTP; pH 7.3.  
Measurements were performed with an Axoclamp 2B amplifier and LabVIEW-RT 8.0 software.  
Voltage responses were induced with 1 sec current steps ranging from -120 pA to 120 pA.  
Virtual excitatory synapses were implemented according to Isyn(t) = k x gsyn(t) x (VM – Erev).  
Synaptic conductance, gsyn(t), was modeled after the sum of two exponentials, with time 
constants of 1 ms for the rising phase and 7 ms for the falling phase. The synaptic reversal 
potential, Erev, was set to 0. Synaptic strength was adjusted to have a peak amplitude of 1, by 
scaling the dimensionless factor k. Thresh-gsyn, which is the minimal amount of conductance 
needed to cause an action potential, was determined with an automated binary search routine that 
systematically adjusted the strength of the virtual EPSP until threshold-gsyn was determined 33. 
2.5 VIABILITY ASSAYS 
In transfected, viable neurons Luciferase reporter genes were used as a marker of cell 
viability 7,25,26. Twently-four hours after transfection with luciferase and a plasmid of interest, 
cells were exposed to activated microglia to induce neuronal toxicity 27. Then cells were assessed 
for viability using Steadylite luciferase substrate (Perkin Elmer, Boston, MA) per manufacturer’s 
instructions. In this assay, viability is proportional to luciferase luminescence. 
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2.6 IMMUNOPRECIPITATION AND IMMUNOBLOTTING 
Twenty-four hours after transfection, CHO cells were lysed (Upstate buffer, Lake Placid, 
NY), centrifuged and supernatants were collected and stored at -80oC. Protein concentration was 
measured using a bicinchoninic acid assay (Pierce, Rockford, IL), equal protein was pre-cleared 
with protein A plus G agarose beads (Santa-Cruz, Santa Cruz, CA), and incubated with Kv2.1 
monoclonal antibody (NeuroMab, Davis, CA) and the bead slurry. Samples consisting of beads 
bound with immuno-complexes were rinsed and prepared for reducing sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS PAGE) by addition of sample buffer (625 mM Tris, 
25% glycerol, 2% SDS, 0.01% bromophenol blue and 5% β-mercaptoethanol), and boiling at 
100OC for 5 minutes. 
 
Samples were then separated on 8% SDS PAGE gels (Mini Protean 3 System, Bio-Rad, 
Hercules, CA), transferred to 0.2 µm nitrocellulose membranes (Bio-Rad), blocked with 1% 
Bovine Serum Albumin (BSA) in PBS with 0.05% Tween 20 (PBST) at room temperature for 1 
hour and probed with either Kv2.1, phosphotyrosine antibodies (BD Biosciences, San Diego, 
CA), or immunoaffinity-purified rabbit serum directed at phosphorylated S800 of Kv2.1 15. 
Infrared fluorescent goat secondary antibodies (Li-Cor, Lincoln, NE) were used to visualize 
proteins. Optical density was measured using an Odyssey infrared imaging system (Li-Cor) with 
its improvement over film techniques in non-linear measurement and ability to more accurately 
measure and elicit quantitative results. 
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3.0  RESULTS 
3.1 NS5A1B SUPRESSES DELAYED RECTIFIER K+ CURRENTS IN CORTICAL 
NEURONS AND IS NEUROPROTECTIVE 
HCV NS5A1b modulates Kv2.1 activity in cortical neurons. Mankouri et al. (2009) found 
that a hepatocyte-derived cell line expressing HCV NS5A of the 1b genotype demonstrated 
significantly  reduced (~70%) K+ currents as compared to untransfected or vector-expressing 
cells. This effect was not restricted to cells that support HCV RNA replication, as HEK293 cells 
transfected with virus protein along with Kv2.1 showed similar effects. To assess whether 
suppressed Kv2.1 activity is also seen in neurons transfected with NS5A1b, we used whole-cell 
electrophysiological recordings to measure K+ currents in cortical cultures. As in the hepatoma 
cells, there was a significant  decrease (~60%) in voltage-gated, delayed rectifier K+ current 
densities in neurons transfected with a NS5A1b-GFP fusion protein under basal conditions 
(Figure 3A). This indicates that NS5A1b expression inhibits Kv2.1 channel activity in cortical 
cultures, as the channel is the primary mediator of delayed rectifier K+ currents in this cell type 7. 
It also suggests that the viral protein is interfering with expression or with normal trafficking of 
channels at the surface of neurons. 
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NS5A1b limits the K+ current surge during injury. During oxidant-induced apoptosis, 
neurons undergo a large Zn2+- and p38-dependent efflux of potassium via delayed rectifying 
channels, signified by a large current enhancement 4,6. Mankouri et al (2009) reported a limited 
K+ current surge in NS5A-expressing hepatoma cells compared to vector-expressing controls in 
the presence of 2,2'-dithiodipyridine (DTDP), an oxidant apoptogen that leads to potassium 
current enhancement 4. Therefore, we investigated whether neurons transfected with NS5A 
would be protected from induced oxidative stress and intracellular Zn2+ release, as demonstrated 
by a decreased K+ current surge. For these studies we used activated microglia (AMG), which 
produces comparable K+ current enhancement to DTDP through a similar cell death pathway, but 
within a more physiologically based system. Knoch et al. (2008) reported that AMG co-cultured 
in trans-wells with cortical neurons induce oxidative stress from reactive oxygen and nitrogen 
species, subsequent neuronal intracellular zinc release, and robust apoptotic activation, including 
a pronounced voltage-gated K+ current surge. Here we show that vector-expressing neurons 
exposed to AMG show robust K+ current enhancement (Figure 3A). Similarly, AMG-exposed 
cells transfected with NS5A1b showed an increased average current density compared to 
NS5A1b-expressing cells not exposed to the oxidant.  Nevertheless, currents evoked by 
NS5A1b-expressing neurons exposed to microglia were significantly lower than in activated, 
vector-transfected cells, and were nearly identical to currents seen in neurons expressing vector 
without AMG (Figure 3A). Thus, NS5A limited the overall extent of K+ current enhancement, 
which could be neuroprotective. 
 
NS5A expression does not alter intrinsic neuronal properties. Since we saw significant 
changes in K+ currents under basal cellular conditions in the presence of NS5A1b, we next 
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assessed changes in intrinsic electrical properties, in collaboration with Dr. John P. Horn and 
Mitchell G. Springer. Because Kv2.1 activation is voltage-dependent, we expected that resting 
membrane potential, input resistance, and threshold synaptic conductance in neurons transfected 
with NS5A would be consistent with control cells. Indeed, levels in NS5A1b-expressing cortical 
cells were comparable to vector or untransfected cells in each of these parameters (Figure 3B). 
However, as is consistent with decreased Kv2.1 activity, we saw slightly increased firing 
frequencies as a function of current in cells transfected with NS5A1b as compared to those 
transfected with its parent vector (Figure 3C). Thus, the actions of the viral protein may affect 
integrative characteristics of cortical neurons. 
 
NS5A1b maintains viability in neuronal cultures exposed to activated microglia. Injured 
neurons expressing NS5A demonstrate limited overall current enhancement in voltage-gated K+ 
channels, required for neuronal apoptosis. Thus, we investigated whether this translated into 
protection from cell death following microglial-induced toxicity. In order to perform this study, 
we utilized a luciferase reporter assay in which luciferase activity correlates with viability, as 
previously confirmed with random field counts within GFP transfected cells 7,25,26. Neurons were 
transfected with a luciferase-expressing plasmid and either NS5A1b or vector. In this assay, cells 
are injured with either kainic acid, a control non-apoptogenic stimulus to produce the maximum 
neuronal cell death 34 (results not shown), or with LPS and IFN-γ activated microglia that 
induced 45-50% cell death in control cells within 24 hours. In contrast to vector-expressing cells, 
we found that cells transfected with NS5A1b were virtually immune to AMG insult (Figure 3D). 
Along with our electrophysiological data, and previous studies linking viability to limitation of 
the K+ current surge 2,6,7, these studies demonstrate that limiting threshold levels of K+ current 
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enhancement is sufficient to confer neuroprotection. These data further support a mechanism by 
which NS5A inhibits neuronal apoptosis by interfering with Kv2.1 channel function. 
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Figure 3. NS5A interferes with K+ channel function and is neuroprotective.  
(A) (Top) Representative whole-cell K+ currents in rat cortical neurons in culture, evoked by 10 
mV incremental steps (-80 to +50 mV).  Neurons were transfected with vector (VEC) or NS5A 
(genotype 1b) plasmids and exposed to vehicle or activated microglia (AMG). Scales are 1 nA 
and 5 ms. (Bottom) Mean (± s.e.m.; n=7-20 cells per group, 49 cells total) current densities (at 
+10 mV) from cells such as those shown above (normalized to cell capacitance). 
ANOVA/Bonferroni, all p<0.001; ***VEC vs. NS5A, +VEC vs. VEC/AMG, +NS5A vs. 
NS5A/AMG and ++VEC/AMG vs. NS5A/AMG.  (B) Current clamp was used to measure the 
resting membrane voltage (Vm), input resistance (Rin) and threshold synaptic conductance 
(Thresh-gsyn) in untransfected (UT) and vector-expressing cells (VEC) or NS5A1b-transfected 
neurons (mean ± s.e.m.; n=5-8 cells per group). Scales are 20 mV and 500 ms (C) Repetitive 
firing was recorded for VEC and NS5A1b transfected neurons using 1 sec depolarizing current 
steps of increased amplitudes. (Top) Traces are representative of neurons in each group at three 
different depolarizing current stimuli (n=8). (Bottom) Frequency-current relationships were fit to 
nonlinear regressions and compared using an F test. NS5A1b transfected neurons have a 
significantly higher repetitive firing frequency as a function of current when compared to VEC 
transfected neurons (P<0.01). (D) Rat cortical neurons expressing NS5A1b, but not empty vector 
(VEC), are protected from exposure to AMG. Transfection is performed, and cells are exposed to 
AMG after 24h. Cells are then harvested and assayed for luciferase activity as an index of cell 
viability 35 24h post-AMG exposure. Shown are mean (± S.D.) luciferase values (counts per 
second, CPS) of a representative experiment, performed in quadruplicate; *p < 0.05, 
ANOVA/Dunnet.  Inset, mean ± s.e.m. of viability for a total of 7 independent experiments (each 
performed in quadruplicate), expressed as a percent of control; **p<0.01, paired t-test. 
3.2 NS5A1B INHIBITS SRC BUT NOT P38 PHOSPHORYLATION OF KV2.1-
ENCODED K+ CHANNELS 
3.2.1 P38-dependent Kv2.1 S800 phosphorylation is not affected by NS5A1b. 
To elucidate the specific molecular mechanism of modulation of the Kv2.1-dependent 
apoptotic pathway by NS5A1b, we used Chinese hamster ovary (CHO) cells which do not 
possess voltage-gated K+ channels 8. Thus, any changes in voltage-gated currents that we 
detected could be attributed to exogenously expressed channels. Importantly, CHO cells, which 
are normally resistant to oxidative injury, follow an apoptotic pathway similar to cortical cells 
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when expressing Kv2.1, including the potassium current surge 7,14. Indeed, as in neurons, we 
found that CHO cells co-expressing NS5A1b, along with Kv2.1, have depressed basal K+ 
currents compared to those transfected with Kv2.1 and vector alone (Figure 4A). 
 
Mankouri et al. (2009) suggests that NS5A confers its effects through the modulation of 
p38 MAPK phosphorylation of Kv2.1 S800 (see Figure 2), a process known to be required for 
the potassium current surge 14,15. We thus began testing this putative mechanism using CHO cells 
expressing a mutant Kv2.1 channel. When the serine at the 800 residue is mutated to a positively 
charged amino acid (such as glutamate), it mimics constitutive phosphorylation at this site, 
independent of p38 activity 15. Based on results by Mankouri et al (2009),  . However, although 
Kv2.1 (S800E) currents were increased, mimicking the oxidant-induced neuronal current surge, 
we noted similar inhibitory effects with NS5A1b as were seen in Kv2.1 wild-type channels 
(Figure 4A). This seemed to indicate a different mechanism of NS5A modulation of K+ channels 
than was proposed by Mankouri et al. (2009). 
 
Consequently, we moved to a biochemical approach to investigate the level of Kv2.1 
S800 phosphorylation after p38 induction, in the presence or absence of NS5A1b. After 
immunoprecipitation with a Kv2.1 antibody, we measured p38 phosphorylation by using a 
phospho-specific antibody that our laboratory had previously generated toward the S800 site of 
Kv2.1 15. Indeed, collaborative studies with Kai He demonstrated that NS5A1b did not block 
phosphorylation at the S800 site in CHO cells expressing Kv2.1, regardless of p38 over-
expression. A non-phosphorylatable mutant, Kv2.1 (S800A) 15, was used as a control for the 
specificity of the antibody (Figure 4B). These, along with electrophysiological data in Figure 4A, 
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led us to the conclusion that the modulation by NS5A1b of neuronal and Kv2.1-expresssing 
CHO cell K+ currents is not likely due to interference with p38 activation at Kv2.1 S800. 
3.2.2 P38 NS5A interferes with Src-mediated phosphorylation of Kv2.1 Y124. 
A variety of kinase systems interact with Kv2.1 to affect its activity 36-38. For example, 
phosphorylation by Src and dephosphorylation by protein tyrosine phosphatase work in concert 
to up and down-regulate activity of the K+ channel at a specific tyrosine 38,39. Redman et al. 
(2009) demonstrated that this tyrosine (Y124) is required, in addition to the S800 residue, for K+ 
current enhancement leading to oxidant-induced apoptosis in cortical neurons. Thus, the surge is 
triggered, in part, by concurrent activation of Src and p38 kinase pathways.  
 
There are two class II polyproline motifs conserved throughout all NS5A genotypes that 
interact with Src-homology 3 (SH3) domains to suppress the host Src-like kinases Hck, Lck and 
Lyn 40. Consequently, we investigated whether the viral protein inhibited Src-mediated 
processes. To test this, we expressed channels carrying a mutation that replaces the tyrosine with 
a phenalaline, rendering the channel non-phosphorylatable at the Y124 site (Kv2.1 (Y124F); note 
that phospho-mimicking mutants are non-functional) 18. Unlike the current inhibition seen in 
NS5A1b-expressing CHO cells harboring wild type Kv2.1 or Kv2.1 (S800E) mutants, potassium 
currents of cells expressing Kv2.1 (Y124F) are not inhibited by NS5A1b (Figure 4A). This 
suggests that the viral protein interferes with Src phosphorylation of residue Y124 - a signaling 
step that is necessary for the large surge of Kv2.1 currents during apoptosis 15, and which could 
also be necessary for channel trafficking under basal conditions.  
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As a result, we investigated whether NS5A 1b can block Src phosphorylation of Kv2.1. 
Again, in collaboration with Kai He, we used Kv2.1 immunoprecipitation in CHO cells over-
expressing Src in the presence or absence of NS5A1b. We then probed with a phosphotyrosine 
antibody, since measures to generate a phospho-specific Kv2.1 Y124 antibody had previously 
proven unsuccessful 18. The phosphotyrosine signal, upregulated with overexpression of Src, was 
significantly decreased in those cells transfected with NS5A1b (Figure 4C). This is in accordance 
with our electrophysiological results (Figure 4A), as well as findings that suggest over 80% of 
Src phosphorylation of the channel is targeted to this residue 38. Taken together, these data 
demonstrate a likely Y124, Src-dependent mechanism for NS5A1b Kv2.1 inhibition.  
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Figure 4. NS5A1b inhibits Src, but not p38, phosphorylation of Kv2.1.  
(A) (Top) Representative whole-cell currents (-80 to +30 mV step) in Chinese hamster ovary 
(CHO) cells expressing Kv2.1, Kv2.1(S800E), or Kv2.1 (Y124F) together with either VEC or 
NS5A1b (marked by a +). Note decreased currents in NS5A1b-expressing cells, except in the 
case of the Kv2.1(Y124F) mutant.  Scales are 5 nA and 5 ms.   (Bottom) Average K+ current 
suppression by NS5A1b co-expression, expressed as a % of the average currents present in 
vector expressing cells; n=9-19 cells per group (82 cells total); *p<0.05, significantly different 
from the other two groups, ANOVA/Dunnet. (B) CHO cells were co-transfected with 
Kv2.1(S800A), Kv2.1, p38, NS5A1b or vector. Kv2.1 immunoprecipitates were run on SDS-
PAGE and probed with a phospho-specific antibody recognizing the phosphorylated form or 
residue S800 41.  Kv2.1 phosphorylation at S800 was increased by p38 over-expression in wild-
type, but not in mutant channels.  Co-expression of NS5A1b was ineffective in blocking the 
actions of p38.   (Top) Representative immunoblot; (Bottom) summary and quantification of 
results in three independent experiments, normalized to total Kv2.1 protein; **p<0.01, 
ANOVA/Dunnet vs. Kv2.1 control (third bar).  (C)  CHO cells were co-transfected with Kv2.1, 
Src, NS5A1b or vector. Kv2.1 immunoprecipitates were run on SDS-PAGE and probed with a 
phosphotyrosine.  Tyrosine phosphorylation of Kv2.1 was increased by Src over-expression.  
Co-expression of NS5A1b in this case significantly inhibited the actions of Src.   (Top) 
Representative immunoblot; (Bottom) summary and quantification of results in three 
independent experiments; **p<0.01, ANOVA/Bonferroni vs. Src/vector group (second vs. third 
bar). 
3.3 NS5A ACTIONS ARE GENOTYPE-SPECIFIC. 
As we found the Src-phosphorylated Kv2.1 residue Y124 to be the likely target of NS5A, 
and as the viral protein is known to interact with host Src-like proteins through a conserved 
polyproline motif, we next utilized an NS5A mutant in which the conserved prolines had been 
changed to alanines, termed NS5A (PA2). Hepatoma cells harboring an HCV replicon with this 
same mutation (repliconPA2) have normal potassium currents, compared to cells harboring the 
non-mutated replicon 20. Electrophysiological results in cortical neurons with NS5A (PA2) 
mutants showed no current inhibition (Figure 5A), apparently suggesting that abolishing Src-like 
binding is sufficient to render NS5A ineffective at modulating K+ currents in this system. 
However, we noted that this NS5A (PA2) mutant is of a different genotype (1a vs. 1b) 42, and 
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when comparing currents generated from cells transfected with the wild type NS5A1a to those 
expressing the NS5A1a (PA2) mutant, there was no significant difference, i.e. the current 
inhibition was absent in even the wild type cells (Figure 3A). In further collaboration with Kai 
He, NS5A1a also did not inhibit Src-mediated tyrosine phosphorylation of Kv2.1 channels 
expressed in CHO cells (Figure 5B) as we had seen in NS5A1b-expressing cells (Figure 4C). 
These results suggest that there are differences between NS5A genotypes that account for the 
lack of suppression of the basal potassium currents. Indeed, as the genotypes share only 80% 
sequence homology, there is 20% genotypic disparity that could account for observed differences 
43. Moreover, NS5A1a did not confer similar neuroprotection as its 1b counterpart in cortical 
neurons exposed to AMG (viability was 69.8 + 2.3% of control; n=3; compare to Figure 3B). 
Together, these data indicate that the inhibitory effects of NS5A on Kv2.1-mediated currents are 
genotype-specific, and that the K+ channel inhibitory effect of NS5A1b is a critical component of 
its anti-apoptotic effects.  
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Figure 5. Genotype 1a of NS5A is ineffective in blocking K+ currents in neurons, or preventing SRC 
phosphorylation of Kv2.1.  
(A)  Representative whole-cell K+ currents in rat cortical neurons in culture, evoked by 10 mV 
incremental steps (-80 to +50 mV).  Neurons were transfected with vector (VEC), NS5A1a, or 
NS5A1a(PA2) plasmids (Top).  Scales are 3 nA and 25 ms.  (Bottom) Mean (± s.e.m.; n=14-16 
cells per group; 44 total cells) current densities (at +10 mV) from neurons transfected with empty 
vector, NS5A (genotype 1a) or a mutant (PA2) of NS5A1a lacking the polyproline motif that has 
been shown to interact with Src-like kinases. (B) Experiments similar to those shown in Figure 
2C, illustrating the lack of inhibition of Src phosphorylation of Kv2.1 channels in CHO cells 
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expressing NS5A1b (n=3); **p<0.01, ANOVA/Dunnet; all groups are significantly different 
from Kv2.1+vector group (first bar). 
 
3.4 CK2 PHOSPHORYLATION OF NS5A MAY BE REQUIRED FOR K+ CURRENT 
MODULATION. 
The modulation of K+ channel activity, Src-mediated phosphorylation, and apoptosis in 
NS5A1b but not 1a-expressing cells led us to speculate that these discrepancies are due to 
genotypic divergence. Moreover, genotype disparity of HCV correlates with differences in virus 
virulence and cancer incidence 44,45, as well as phosphorylation profile of the NS5A protein 46. 
Likewise, functions of the viral protein are dependent on specific phosphorylation events 47; 
however, the precise role phosphorylation plays in  NS5A’s subsequent interactions with host 
proteins has not been fully elucidated. In vitro cell-free and transfected cell models show that the 
constitutively active, pleiotropic kinase CK2 (formerly known as casein kinase 2) phosphorylates 
NS5A 46,48, and it is thought to be the primary kinase targeting the viral protein for basal 
phosphorylation 43,49,50. Intriguingly, there is some heterogeneity in the phosphorylation profiles 
of CK2 between genotypes 1a and 1b, trending toward more predicted CK2 residues in the 1b 
protein 46.  
 
Due to the apparent constitutive activation of CK2 48, we used the specific inhibitor 5-
oxo-5,6-dihydroindolo-[1,2-a]quinazolin-7-acetic acid (IQA) to reduce expression of the protein, 
and to see if this translates to reduced K+ current inhibition previously seen in cells with NS5A1b 
expression. IQA (10 µM) was added with conditioned media after transfection of neurons with 
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NS5A1b or vector, and was present in the external recording solution for electrophysiological 
measurements. In the presence of IQA, there was no significant difference in K+ current densities 
in NS5A1b-expressing or vector-expressing cortical cells (Figure 6). Thus, CK2 suppression 
blocked basal current modulation previously seen in NS5A-expressing cells. This preliminary 
result suggests that phosphorylation of the viral protein by CK2 is necessary for conferred anti-
apoptotic properties by NS5A1b.  
 
 
 
 
 
 
Figure 6. CK2 inhibibtion blocks current modulation by NS5A1b.  
Mean (± s.e.m.; n=6-20 cells per group) current densities (at +10 mV) from neurons transfected 
with empty vector (eGFP) or NS5A1b, and treated with 10 µM 5-oxo-5,6-dihydroindolo-[1,2-
a]quinazolin-7-acetic acid (IQA; CK2I). First two bars are experiments from Figure 3A.  
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4.0  DISCUSSION 
The results in this study show that the HCV-derived protein NS5A genotype 1b 
modulates Kv2.1 channel activity in cortical neurons and CHO cells, two cell types which lack 
the ability to replicate the virus. Furthermore, NS5A1b limits the magnitude of the pro-apoptotic 
K+ current surge, and confers neuro-protection following AMG-induced toxicity. These findings 
are genotype-specific, as NS5A1a does not confer the same anti-apoptotic effects. Finally, host-
cell modifications of the virus protein, such as phosphorylation, may play a role in anti-apoptotic 
properties, as treatment with a specific kinase inhibitor disrupts NS5A1b basal K+ current 
inhibition.  
 
HCV, which affects over 3% of the world’s population, induces a chronic liver infection 
that causes serious and persistent liver disease in the majority of people infected. In many cases, 
it leads to cirrhosis and hepatocellular carcinoma 51. The HCV non-structural protein 5A (NS5A) 
is a highly studied, potential therapeutic target for treatment of this disease, as it is required for 
virus replication. Nevertheless, the full spectrum of NS5A function is unknown. Viral proteins 
must be adaptable to different host cell environments and be able to complete varying tasks at 
specific times in the life cycle of both the virus, and host. Additionally, virus infection that 
translates to host cell death is not well suited for propagation of the virus itself. NS5A is one of 
10 proteins processed from the HCV RNA genome, and has previously been linked to anti-
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apoptotic properties 40. Recently, a mechanism was defined 20 that may explain how this protein 
promotes viral replication and persistence. Moreover, interference with K+ channels is currently 
the only proposed mechanism for how NS5A blocks apoptosis in the viral system.  
 
NS5A, a 60 kDa protein required for viral replication, is divided into 3 domains.  Domain 
I is the only domain to have been crystallized 52, and thus more is known about this N-terminal 
domain of the protein. Within this domain, and most proximal to the N-terminus, sits a 
membrane-anchoring amphipathic alpha helix necessary for viral replication complex formation 
53-55, and likely necessary for membrane trafficking of the epidermal growth factor receptor 56. 
Domain I also contains a zinc binding region that is required for HCV replication and is 
conserved throughout all HCV genotypes. However, the full functional range of NS5A as a zinc 
metalloprotein is not well understood. Contained within this region are a number of cysteine 
residues important for viral replication complex assembly 52,57. Other salient features of the 
protein are caspase/calpain cleavage sites in domain I 58,59, and the aforementioned class II 
polyproline motifs, located between domains II and III. Additionally, within NS5A there is a 
highly conserved area of hyperphosphorylation within domain II of the protein, and two basal 
phosphorylation motifs. The most conserved of the latter among genotypes is the more amino-
terminal region, and the least conserved lies in domain III near the c-terminus 60,61. 
Hyperphosphorylation is required for viral RNA replication, and is also dependent upon other 
HCV proteins, namely NS4 62,63; however,  basal phosphorylation is less well understood. This is 
generally due to the fact that, as mentioned, little is known about the more c-terminal domains, 
particularly domain III 64. Figure 7 highlights some important features of NS5A.  
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Figure 7. Features of the NS5A protein.  
NS5A contains three domains, separated by two low complexity sequences consisting of 
repetitive amino acids. Motifs include a membrane-anchoring alpha helix, a zinc-binding motif, a 
cleavage site targeted by proteases, and Class II poly-proline motifs (adapted from Moradpour et 
al., 2005 and He et al., 2006 by Elias Aizenman). 
 
 
 
Defining the molecular domains of NS5A necessary for restricting Kv2.1 function is of 
primary importance in the potential development of small molecule inhibitors that mimic the 
actions of the viral protein as a neuro-therapeutic strategy. The work presented herein helps to 
define areas of interest based on genotype disparity and presence or absence of effects that block 
cell death pathways. Of interest, genotype 1 (including 1a and 1b) accounts for most forms of 
HCV, especially in the US, and has been associated with more severe liver disease, more 
aggressive disease progression, resistance to therapy and recurrence, and importantly, increased 
incidence of hepatocellular carcinoma in patients exhibiting chronic, active HCV infection 65.  
The anti-apoptotic properties of NS5A1b via its inhibition of Kv2.1 channel function could be 
important contributors towards its increased persistence and association with liver cancer. 
Notably, cell death related to viral persistence is one of the greatest disparities among genotypes, 
particularly between the two type 1 viruses, which share only 80% sequence homology 43. Most 
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sequence differences are found near the C-terminal domain of the protein in domain III 66,67, 
immediately adjacent to the SH3-binding polyproline motifs, which themselves are highly 
conserved among all HCV genotypes 68. Until recently there was no demonstrated function of 
domain III of the NS5A protein, although exchange of multiple serines to unphosphorylatable 
residues disrupts the efficiency of virus production 50,64. Moreover, a specific phosphorylation 
site was discovered to be crucial for virion production, assembly and release, 47, and thus, other 
functions of this region are likely to rely on phosphorylation as well. It has been suggested that 
different phosphorylation profiles are present in NS5A1a and NS5A1b, particularly within the 70 
amino acids that lie most proximal to the C-terminus 69. Because the functions thus far attributed 
to this domain of NS5A are required for the virus life cycle and are well conserved, there is 
likely another function to account for the discrepancy among genotypes, such as viral persistence 
relating to the newly proposed mechanism of apoptotic inhibition through a K+ channel 20. Post-
translational modifications such as phosphorylation events are one potential avenue to 
accomplish this 70.  
 
Much is known about how host proteins interact with NS5A, but there is a paucity of 
information about how this interaction affects the functions of NS5A within the cell. Whether the 
genotype-specific effects of NS5A1b on K+ channel modulation are due to specific amino acid 
differences, phosphorylation levels, or both, remains to be established. NS5A is known to 
extensively interact with host proteins, and the kinase CK2 has been predicted to phosphorylate 
specific sites on the C-terminus of the protein, differentially by genotype 46,49,50,71. In addition to 
intrinsic viral proteins that process NS5A, such as the NS3/NS4A serine proteinase complex 72-
74, host proteins also play a role in its processing. As mentioned, one way in which this virus 
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protein is acted upon by host proteins is through phosphorylation by the kinase CK2 46,49,50,71. 
Although there are many conserved phosphoacceptor sites between viral genotypes, one of 
which is required for effective virion production 47, there is some heterogeneity in the 
phosphorylation profiles of CK2, between genotypes 1a and 1b, trending toward more predicted 
CK2 residues in the 1b protein 46. It is not known how phosphorylation of NS5A proceeds in our 
system;, the kinase is present in the brain at levels higher than any other organ, and is localized 
specifically to neurons within the CNS 43,71,75. It is thought to play a role in a variety of processes 
including p53 regulation and learning and memory 76. CK2 is a pleiotropic protein with over 300 
known substrates, and is constitutively active within the cell 48. Thus, differences in 
phosphorylation profile have more to do with the number and location of specific sites, rather 
than activity of the kinase itself. Preliminary results herein showed a dependence on the full 
expression of CK2 for modulatory effects on basal delayed rectifier K+ channels (Figure 6). CK2 
is also thought to modify other virus proteins 43,49,50 and thus its activity may be required for 
significant viral actions within multiple cell types. The functional significance of NS5A 
phosphorylation by CK2 has remained elusive despite years of study. Continued work in this 
system could elucidate further mechanisms and requirements for the anti-apoptotic properties of 
NS5A via this pathway our laboratory has defined over the past 10 years (Figure 1).  
 
Phosphorylation events are known to regulate viral-host cellular events such as caspase 
cleavage. As mentioned, there are caspase/calpain cleavage sites in domain I of NS5A that may 
be used to target portions of the viral protein to various cellular positions during injury 58,59. A 
recent paper by Turowec et al (2011) described overlapping caspase cleavage and CK2 
phosphoylation motifs. It has been previously established that kinase substrates become more or 
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less likely to be cleaved by caspase, dependent on their phosphorylation profile in overlapping 
motifs, and that these interactions play a role in cell survival and cancer 77-79. In fact, CK2 
phosphorylation residues often overlap with caspase cleavage sites, and phosphorylation can 
prevent or increase the likelihood of protease cleavage at specific sites 80. This might be a link 
between two post-translational modifications of the virus protein, and could be required for cell 
death prevention. Of note, sequence observations confirm that the cleavage site contained within 
NS5A is a predicted site of CK2 phosphorylation. Furthermore, this CK2 phosphorylation site is 
only predicted in viral protein sequences of the 1b genotype 46. 
 
Understanding the pathways and specific mechanisms of how NS5A blocks neuronal 
apoptosis is crucial to the design of small molecule or peptide mimetics that could be used to 
block the Kv2.1 K+ surge following neuronal injury and to treat oxidative stress in neurons. 
NS5A is known to disturb various signaling pathways in cells, including MAPK inhibition 56,81,82 
and PI3K activation 42. It was thought to mediate these effects primarily through a polyproline 
motif (PxxPxR) at the C-terminus, which binds to SH3 domains of proteins, including Src-family 
kinases, amphiphysin II, as well as other kinases 73,83,84. However, distinct to the mechanism 
proposed by Mankouri et al. (2009), our results suggest that the K+ current modulatory effects of 
NS5A are not mediated by the SH3-binding, polyproline motifs in this protein, since both the 1a 
and 1b genotypes contain these sequences, and NS5A1a lacked function in our assays.  In 
addition, while the SH3-binding domain of NS5A effectively binds and inhibits the action of the 
Src-family kinases Hck, Lck and Lyn, it has not been shown to bind Src itself 85.  However, it 
was recently reported that Src is required for the interaction between NS5A1b and the HCV 
RNA-dependent polymerase NS5B.  NS5A1b can bind Src, not at the kinase SH3 domain, but at 
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a different, SH2 domain, although the specific NS5A1b-SH2 binding interaction region has yet 
to be defined 86.  
 
A recent study describes two additional Kv2.1 tyrosine residues phosporylated by Src 87 
which likely account for the minimal phosphotyrosine signal in cells transfected with Kv2.1 
(Y124F) after Src induction 38. Indeed, studies with Kai He in our laboratory in CHO cells 
transfected with Kv2.1 (Y124F) and Src confirm a consistent, but slight (~17% of wild type 
cells) tyrosine phosphorylation signal (phosphotyrosine levels were 0.037 ± 0.003 r.u., n=3; 
compared to 0.212 ±  0.019 r.u., n=3, from Figure 4C; p<0.001, unpaired t test; results not 
shown).  Co-expression with NS5A also inhibited this non-Y124 Src-induced phosphorylation of 
Kv2.1 (Y124F) (0.015 ±  0.004 r.u., n=3; significantly different from vector-expressing cells, 
p<0.05, t test; not shown).  This suggests that the effects of the viral protein may represent a 
general repressive mechanism of the actions of Src. What this means in regards to therapies 
using drugs mimicking NS5A Src-inhibition of the channel is yet to be determined and further 
analysis is critical. The likely requirement for phosphorylated tyrosine residues, in combination 
with the known phosphorylation differences between NS5A1b and NS5A1a 88, could provide 
important clues at defining the mode of action of the viral protein for modulating K+ channel 
function.  This mechanism, which evolved in a virus to prevent cell death, may provide critical 
information for the development of novel neuroprotective strategies to block K+ current-
mediated following injury. 
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